Market Minds Advisory
Vaccines Market

Vaccines Market: Two Opposite Businesses Under One Word

Public tender doses sell for around a dollar and adult private courses for several hundred, decided by entirely different buyers, and most manufacturers run both businesses out of one commercial organisation.

Lead Analyst

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$62.0BMarket Size 2025
2036 FORECAST VALUE$144.6BBase Case , 2026 to 2036
CAGR 2026 TO 20368.0 %Bull 9.2% / Bear 6.8%
INCREMENTAL OPPORTUNITY$77.6BNet 10- year value creation
EXPANSION MULTIPLE2.16x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

One word covers two opposite businesses. A paediatric dose bought through multilateral procurement sells for roughly 1.20 dollars, while an adult private course reaches around 340. The buyers, the pricing logic and the commercial skills required have almost nothing in common. Very few organisations acknowledge that plainly.
East Asia holds 28% of value on Chinese domestic programme scale and Japanese and Korean adult vaccination together, while India produces roughly 46% of global doses by volume and grows fastest at 10.1%. Adult and older adult vaccines grow at 12.0%, half again the market rate of 8.0%, against uptake that reaches only about 34% of people for whom vaccination is already recommended. Access rather than persuasion limits that number.
Concentration reaches 74% because biological manufacturing at scale excludes most entrants. Cost of goods runs near 24% of revenue, far above small molecule economics, and capacity is committed years before any tender outcome is known. Success also shrinks the market, which no other therapeutic category has to plan around. A vaccine that works lowers disease incidence and therefore the visible reason to be vaccinated. Sentiment hardens where programmes worked best. Success erodes its own market.
Market Definition
The market covers human vaccines for prevention and therapeutic use, including paediatric routine immunisation, adult and older adult vaccines, influenza vaccines, travel and occupational vaccines, outbreak and pandemic preparedness vaccines, and therapeutic and cancer vaccines. Veterinary vaccines, monoclonal antibody prophylaxis, immunoglobulin products, adjuvant and excipient supply sold separately, and vaccine administration services billed independently are excluded from scope.
Base Year Value
$62.0B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
8.0% base case. Bull 9.2%. Bear 6.8%.
Fastest Growth Segment
Adult and Older Adult Vaccines: 12.0% CAGR
Fastest Growth Country
India: 10.1% CAGR
Fastest Growth Region
South Asia and Pacific: 10.2% CAGR
Largest Region
East Asia: 28% of 2025 global value
Market Leaders
Pfizer, Merck & Co, GSK, Sanofi, Moderna. Source: MMA Analysis based on disclosed vaccine franchise revenue, company annual reports 2025.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Vaccines Market Forecast Scenarios

vaccines-market-size-forecast-scenario-1787705468792
Growth from 2020 to 2025 ran at 6.8% and the period is almost impossible to read cleanly. Pandemic vaccine revenue arrived at extraordinary scale and then contracted sharply, which distorted every reported figure across those years. Underneath that, adult vaccination expanded genuinely with new respiratory and shingles products, paediatric programmes held broadly steady, and sentiment toward vaccination became more contested across several developed markets.
The 8.0% base case rests on three mechanisms. Adult and older adult vaccination keeps expanding as new products reach recommendation and as pharmacy administration removes the access friction that limits uptake more than persuasion does. Travel and occupational demand keeps recovering and growing. And Asian domestic programmes keep broadening as national immunisation schedules add products that were previously private purchases only. None of the three requires a new platform or a new pathogen.
The bull case at 9.2% assumes adult uptake improves materially toward recommendation levels, which would be worth more than any new product launch in the category. The bear case at 6.8% is sentiment hardening further in developed markets while public procurement pricing tightens, which would compress both businesses at once without any offsetting growth to absorb the manufacturing capacity already committed.

A Dollar Or Three Hundred

The same manufacturers run two businesses that share nothing but a word. A paediatric dose sold through multilateral procurement clears at around 1.20 dollars against volume commitments negotiated years ahead, while an adult course in a private market reaches roughly 340 dollars and is decided by physician recommendation and patient willingness. One is a commodity tender business and the other is consumer health with a clinical coat.
FIVE-FIRM CONCENTRATION74%Share of vaccine revenue held by the leading manufacturers
ADULT COURSE PRICE$340Typical private market price for an adult vaccination course
TOP PRODUCING COUNTRYIndia 46%Indian share of global vaccine doses produced by volume
PUBLIC TENDER DOSE PRICE$1.20Typical price per dose under multilateral procurement arrangements
ADULT UPTAKE RATE34%Recommended adult vaccinations actually received by eligible people
COST OF GOODS SHARE24%Portion of vaccine revenue consumed by biological manufacturing
Manufacturing is where this category differs most from the rest of pharmaceuticals. Cost of goods runs near 24% of revenue against a fraction of that for small molecules, because biological production, fill-finish and cold chain are all genuinely expensive. Capacity is committed years before any tender outcome is known. India produces roughly 46% of global doses on exactly that scale logic.
Adult uptake is the largest available opportunity and almost nobody treats it as a distribution problem. Only around 34% of people receive vaccinations already recommended for them, and the gap closes far more reliably through pharmacy administration and standing orders than through any further clinical evidence. Sentiment has also become more contested in several developed markets, which is a genuine commercial variable.
"A dollar twenty and three hundred and forty dollars, same factory, same word on the box. Almost nobody organises the commercial side as the two entirely different businesses that they obviously are."
Director, Vaccines and Immunisation Practice · MMA Healthcare Practice · August 2026

Market Trends

Adult Uptake Is Distribution Not Persuasion

Only about 34% of eligible people receive adult vaccinations already recommended for them, and the gap closes far more reliably through pharmacy administration, standing orders and default scheduling than through further clinical evidence or campaigns. Growth at 12.0% follows access changes rather than any argument being won. Manufacturers investing in medical communication rather than in administration channel access are addressing a problem that was never primarily about what people believe. The access route is measurably cheaper per additional person vaccinated, and the volume arrives within a season rather than across years of campaigning.
Market Impact: Produces 46% of global doses

Capacity Commitments Precede Every Tender Outcome

Biological manufacturing capacity has to be built and validated years before a procurement round is decided, and cost of goods near 24% of revenue leaves little room to carry underused facilities. A lost tender therefore strands capacity rather than simply losing a contract. That asymmetry favours manufacturers with diversified portfolios across public and private markets, and it punishes single-product specialists in a way that is rarely visible until a tender round goes against them. That exposure is rarely visible until a procurement round actually goes the wrong way. Diversity protects it.
Market Impact: Removes 3 steps from access

Market Opportunities and Growth Drivers

Asian National Schedules Absorb Previously Private Products

National immunisation schedules across China, India and Southeast Asia have added products that were previously available only through private purchase, which converts small paid volumes into very large tendered ones at much lower unit prices. India grows fastest of any country at 10.1% and already produces roughly 46% of global doses by volume. Revenue per dose falls sharply while total volume rises, which suits manufacturers with the scale to absorb that trade and nobody else. Only manufacturers with genuine scale can absorb that trade at all. Others simply cannot. Scale decides participation.
Market Impact: Erodes demand across 2 generations

Pharmacy Administration Removes Adult Access Friction

Allowing pharmacists to administer adult vaccines removes an appointment, a travel decision and a scheduling delay from a process where each of those steps loses people who intended to be vaccinated. Uptake responds quickly wherever the change is made, considerably faster than it responds to any communication programme. Growth in adult vaccination at 12.0% tracks that access expansion across markets, and manufacturers who supported the regulatory change captured the volume that followed it. Each removed step retains people who had already intended to be vaccinated and simply never got there.
Market Impact: Spans 2 opposite commercial models

Market Restraints and Challenges

Effective Vaccines Reduce Their Own Perceived Necessity

A vaccine that works lowers disease incidence, which lowers the visible reason to be vaccinated, and no other pharmaceutical category faces that dynamic at all. Root cause is that prevention succeeds invisibly while treatment succeeds visibly. The commercial impact is demand that erodes precisely where a programme has performed best, and sentiment that hardens when the disease itself is no longer remembered. Mitigation runs through outbreak visibility and schedule defaults rather than through argument. Prevention succeeds invisibly and treatment succeeds visibly. Schedule defaults are the practical answer available. Argument achieves very little.
Market Impact: Reaches only 34% of eligible adults

Public And Private Businesses Require Opposite Capabilities

Tender supply at around 1.20 dollars a dose demands manufacturing scale, cost discipline and multilateral relationships, while private adult vaccination at some 340 dollars a course demands physician engagement, pharmacy access and consumer marketing. Root cause is that one word covers two genuinely different commercial models. The impact is organisations optimised for neither, since capabilities transfer poorly between them. Mitigation involves separating the commercial structures, which very few manufacturers have done properly. Very few manufacturers have separated the two structures properly. Capabilities transfer very poorly between them. Separation costs overhead and works.
Market Impact: Consumes 24% of revenue in manufacturing
3 additional market trends, 4 additional growth drivers, and 2 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Segmentation follows target population and purpose: who receives the vaccine and what it is intended to prevent or treat, rather than the technology platform behind it or how it is procured. Six categories cover the market without overlap. Manufacturing platform and procurement route are treated as separate commercial dimensions here. Platform technology sits outside this hierarchy entirely.
vaccines-market-market-share-analysis-1787705469068

Adult and Older Adult Vaccines

Growth at 12.0%, half again the market rate of 8.0%, comes from new respiratory and shingles products reaching recommendation and from pharmacy administration removing access friction, rather than from any change in how persuasive the clinical argument has become. Uptake reaches only around 34% of eligible people even where recommendation already exists, which makes distribution the largest opportunity in the category. Private market pricing near 340 dollars a course makes each additional vaccinated person worth considerably more than a tendered paediatric dose. National schedule inclusion converts that value into volume overnight, which manufacturers holding private positions consistently underestimate until it happens to them. Access rather than evidence is what limits it.
CAGR 12.0%

Travel and Occupational Vaccines

Travel demand recovered after several depressed years and continues growing with international movement, while occupational vaccination expands through employer health programmes and regulatory requirements in healthcare, laboratory and field-based work. Growth at 9.0% follows both. Commercially this behaves like a private consumer category with a clinical gate, since the purchase is discretionary, the price is paid directly or through an employer, and the decision happens in travel clinics and pharmacies rather than through any national immunisation programme. Employer programmes and regulatory requirements in healthcare, laboratory and field-based work carry a growing share of the occupational volume. The purchase is discretionary and decided in travel clinics and pharmacies rather than any national programme.
CAGR 9.0%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

Geography follows programme scale and pricing structure together, which pull in opposite directions. East Asia leads on domestic programme volume, North America follows on adult private pricing, and India grows fastest while producing most doses. Procurement route decides revenue per dose far more than any product characteristic does anywhere.

North America

Adult vaccination pricing is the highest globally, which makes this region 27% of value on a small share of doses administered worldwide. Pharmacy administration is well established and has lifted adult uptake considerably above what physician-only delivery achieved, though it still reaches only about a third of eligible people. Sentiment toward vaccination has become more contested and varies substantially by state and by product, which is a genuine commercial variable. Paediatric programme coverage remains high and stable despite that broader debate. Adult uptake at roughly a third of eligible people is the largest unclaimed opportunity anywhere in the category, and it is an access problem rather than an evidence one.
Share: 27% | CAGR: 7.2% (2026 to 2036)

Western Europe

National immunisation programmes purchase paediatric and adult vaccines through tender at prices well below American private levels, which compresses value against a comparable population. Pharmacy administration is expanding across several countries and lifts adult uptake wherever it is permitted. Sanofi and GSK hold substantial European manufacturing and commercial positions. Health technology assessment applies cost effectiveness reasoning to new adult vaccines, which slows adoption relative to North America even where clinical recommendation is broadly identical. Adult uptake trails North American levels where pharmacy administration has not yet been permitted, which is an access difference rather than any difference in belief. Cost effectiveness assessment slows adult adoption relative to North America even where clinical recommendation is broadly identical between the two.
Share: 22% | CAGR: 6.4% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
vaccines-market-country-cagr-analysis-1787705469454

Running Both Vaccine Businesses Separately

Tender doses clear near 1.20 dollars while adult courses reach around 340, uptake sits at roughly 34% of eligible people, cost of goods runs near 24% of revenue, and capacity precedes every tender outcome. Four levers work on separation, access, capacity risk and schedule inclusion rather than on clinical evidence. One organisation cannot serve both.

Separate The Public And Private Commercial Structures

Tender supply at roughly 1.20 dollars a dose requires manufacturing scale, cost discipline and multilateral relationships, while adult private vaccination at about 340 dollars a course requires physician engagement, pharmacy access and consumer marketing. Those capabilities transfer poorly and organisations running both from one structure are optimised for neither of them. Separating the commercial functions costs overhead and lets each business be run by people who understand what actually decides its outcomes. Overhead is the price of competence. Neither business is served well by a compromise structure, and the compromise is what almost every manufacturer currently operates.
Market Impact: Serves the 2 opposite commercial models entirely separately

Fund Administration Access Not Further Persuasion

Adult uptake reaches only around 34% of eligible people even where recommendation already exists, and it responds far more reliably to pharmacy administration, standing orders and default scheduling than to any communication programme. Manufacturers supporting regulatory change on who may administer capture the volume that follows immediately. Communication budgets are addressing a problem that was never primarily about belief, and the access route is measurably cheaper per additional person vaccinated. Belief was never the binding constraint. Access is measurably cheaper per person reached. Submissions supporting administration change cost little and deliver volume within a season.
Market Impact: Closes a gap affecting 66% of eligible adults

Match Capacity Commitment To Portfolio Diversity

Biological capacity is committed years before any tender outcome is known and cost of goods near 24% of revenue leaves nothing to carry an underused facility. A lost tender strands capacity rather than merely losing a contract. Manufacturers with portfolios spanning public and private markets redeploy that capacity while single-product specialists cannot. Building diversity into capacity planning rather than into product strategy alone is what actually protects a facility through a bad procurement round. Diversity is a capacity decision. Product strategy does not substitute for capacity planning here. A facility is a decade-long commitment.
Market Impact: Protects the whole 24% cost of goods exposure

Work Schedule Inclusion Before Private Launch Pricing

National schedule addition converts small private volumes into very large tendered ones at a fraction of the price, which is transformative for volume and brutal for revenue per dose. Manufacturers who plan for that transition set private pricing knowing it will be superseded, while those who anchor on private pricing find schedule negotiations impossible later. Roughly 5 major national schedules drive most of that conversion, and each is worked years ahead of any decision. Programme managers describe late repricing as very difficult to accept. Each is worked years ahead. Anchoring on private pricing forecloses it.
Market Impact: Targets the 5 largest national schedules years ahead

Who Controls the Margin Pool

Measured on disclosed vaccine franchise revenue, the five largest manufacturers hold a CR5 of 74%, which reflects biological manufacturing scale and regulatory infrastructure that exclude most potential entrants entirely. Pfizer, Merck, GSK and Sanofi hold broad portfolios across paediatric and adult categories, while Moderna built a position on platform speed. Indian and Chinese manufacturers dominate dose volume without holding comparable revenue share. Dose volume and revenue share sit in entirely different places here.
Three contests define activity. Multilateral and national tender supply competes on cost per dose and on demonstrated capacity, where Indian manufacturers hold a durable cost position. Adult private vaccination competes on physician recommendation and pharmacy access. And outbreak preparedness competes on platform speed and on government contracting rather than on any commercial channel at all. A manufacturer organised for one of those contests is rarely equipped for the others, and the capability each requires overlaps remarkably little with the rest.

Pressure builds as national schedules absorb private products at tender pricing and as sentiment becomes more contested in developed markets. Rankings shift toward manufacturers who separated their public and private commercial structures. Adult access remains the largest unclaimed opportunity in the category. Nobody has claimed it yet.
vaccines-market-company-positioning-matrix-1787705469778

Competitive Moat and Risk Dimensions

MERCK & CO

Moat: Adult Portfolio And Recommendation Depth

Merck holds established adult vaccine positions supported by long-standing physician relationships and recommendation placement built across many product cycles. Adult vaccination priced near 340 dollars a course rewards that depth in a way tendered paediatric supply never can. A competitor with an equivalent product still faces recommendation processes and prescriber habits that took years to establish and change slowly.
MERCK & CO

Risk: Schedule Conversion Price Erosion

National immunisation schedules increasingly absorb products that were private purchases, converting revenue per dose from hundreds of dollars to a small fraction of that overnight. Portfolio strength in the private market provides no protection against a schedule decision. Volume rises and value falls, and the arithmetic frequently works against the incumbent holding the private position.
SERUM INSTITUTE OF INDIA

Moat: Manufacturing Scale Cost Position

Serum Institute produces vaccine doses at a scale and cost position that multilateral procurement depends upon, and India accounts for roughly 46% of global doses by volume largely on that basis. Cost of goods near a quarter of revenue makes scale decisive rather than merely helpful. Competitors cannot approach tender pricing without accepting utilisation levels their own facilities cannot sustain.
SERUM INSTITUTE OF INDIA

Risk: Tender Price Concentration Exposure

Revenue concentrates in tendered supply where price is negotiated down each round and buyers are few and coordinated. Manufacturing scale delivers cost leadership without delivering pricing power against a procurement mechanism designed to extract it. A lost round strands capacity that was committed years earlier against expected volume.

Players Tracked

Prominent Players

Pfizer
Merck & Co
GSK
Sanofi
Moderna

Other Key Players

Serum Institute of India
Bharat Biotech
Sinovac Biotech
Sinopharm
CSL Seqirus
Novavax
Bavarian Nordic
Valneva
Takeda
Biological E
Panacea Biotec
Walvax Biotechnology
Zhifei Biological
Daiichi Sankyo
Emergent BioSolutions

Recent Developments

FEBRUARY 2025

National schedule addition converts private adult vaccine to tender

A national immunisation schedule added an adult vaccine previously available only through private purchase, a public health financing decision rather than any corporate transaction. Volume expanded very substantially while revenue per dose fell to a small fraction of the private price the manufacturer had been receiving beforehand.
Signal: Schedule inclusion multiplies volume and divides price, and the arithmetic often disfavours the private incumbent. Planning matters.
JUNE 2025

Pharmacy administration expansion lifts adult vaccination uptake measurably

A regulatory change permitting pharmacist administration of additional adult vaccines was followed by measurable uptake improvement within two seasons, a policy development rather than any commercial event. Access rather than persuasion had been limiting the number of eligible people actually receiving recommended vaccination. Uptake responded within two seasons.
Signal: Access changes move adult uptake considerably faster than communication programmes have ever managed. Access beats argument every time.
OCTOBER 2025

Manufacturer commits capacity ahead of multilateral procurement decision

A vaccine manufacturer committed additional fill-finish capacity in advance of a multilateral procurement round, an organic capital investment rather than any acquisition. Biological capacity requires years of construction and validation, so commitment necessarily precedes any knowledge of whether the volume will actually be awarded. Commitment precedes any award.
Signal: Capacity precedes tender outcomes, which makes a lost round a stranded facility rather than a lost contract.

What A Dose Costs To Make

Manufacturing cost is unusually high for pharmaceuticals and that shapes everything else. Biological production, purification, fill-finish, quality release and cold chain distribution together account for roughly 24% of vaccine revenue, against a small fraction of that for conventional small molecules. Adjuvants, vials, stoppers and specialised packaging add further. Capacity is validated years ahead of demand, so fixed cost precedes any revenue by a considerable margin.
The volatility that mattered was fill-finish capacity and cold chain cost together. Vial, stopper and specialised glass supply constrained production across the sector during the pandemic period and its aftermath, which Pfizer and Sanofi annual report disclosures reference. Cold chain and energy costs rose sharply through 2022, which IEA industrial energy price data records, and refrigerated distribution is a permanent rather than occasional requirement in this category.

Exposure divides by market weighting rather than by scale alone. Manufacturers weighted toward tendered public supply carry cost of goods against prices negotiated downward each round. Those weighted toward adult private markets carry the same manufacturing base against pricing that absorbs it comfortably. Indian and Chinese producers hold cost positions built on scale and domestic input supply that Western manufacturers cannot approach on tendered volume.
vaccines-market-cost-volatility-analysis-1787705470136

Plan capacity against portfolio not single tenders

Biological capacity is committed years before procurement outcomes are known and cost of goods near a quarter of revenue leaves nothing to carry idle facilities. Manufacturers whose portfolios span public and private markets redeploy capacity when a tender is lost. Single-product specialists carry stranded facilities instead, and that exposure is rarely visible until a procurement round actually goes against them.

Secure fill-finish and container supply contractually

Vial, stopper and specialised glass supply constrained vaccine production across the sector during the pandemic period, at exactly the moment demand was highest anywhere. Committed container and fill-finish arrangements cost inventory and flexibility while protecting the ability to supply awarded volume. Manufacturers relying on spot capacity could not fulfil commitments they had already contracted to deliver.

Price private launches expecting schedule conversion

National schedule addition converts private volumes into tendered ones at a fraction of the price, which is transformative for volume and brutal for revenue per dose received. Manufacturers who anchor launch pricing on the private market find schedule negotiations very difficult afterwards. Planning the transition into launch pricing costs early revenue and preserves the ability to negotiate inclusion later.

Portfolio Architecture for Margin Defence

Margin follows procurement route far more than product characteristics. Tendered paediatric supply earns thinly on very large volumes against prices negotiated downward each round. Influenza vaccines earn moderately with annual reformulation cost. Outbreak preparedness earns through government contracting on different terms entirely. Travel and occupational vaccines earn well through private channels. Adult private vaccination earns most, because pricing near 340 dollars a course absorbs manufacturing cost comfortably.
The tension is that the volume business and the value business need opposite organisations and share one factory. Tender supply demands cost discipline, scale and multilateral relationships. Adult private vaccination demands physician engagement, pharmacy access and consumer marketing. Manufacturers running both through a single commercial structure are optimised for neither, and the capability required in one actively works against performance in the other.

High-value pools sit in three places. Adult private vaccination where access rather than evidence limits uptake to roughly a third of eligible people. Travel and occupational vaccination, which is a private category with a clinical gate. And capacity flexibility across public and private volumes, which is what protects a facility through a tender round that goes the wrong way.

Volume / Commodity-Adjacent

Tendered paediatric routine immunisation and multilateral procurement supply at prices around a dollar per dose. The 9-point range is wide because Indian and Chinese scale producers and Western manufacturers face entirely different cost positions on identical tendered products.
Gross Margin: 22-31%

Premium / Certified

Influenza vaccines, outbreak preparedness supply and national programme adult vaccines purchased through tender at negotiated rather than commodity prices. The 10-point spread separates products with sole or limited supply positions from those facing several qualified competitors in each round.
Gross Margin: 48-58%

Sustainability / Regulatory / Next-Generation

Adult and older adult private vaccination, travel and occupational vaccines, and therapeutic and cancer vaccines. The 21-point range is wide because private adult pricing and early therapeutic vaccine economics differ enormously despite sharing a commercial channel.
Gross Margin: 62-83%
vaccines-market-portfolio-architecture-1787705470438

High-value Sub-segments and Strategic Watch-out

Adult Private Vaccination

Highest value and fastest growth at 12.0%, where pricing near 340 dollars a course absorbs manufacturing cost comfortably and uptake reaches only a third of eligible people. The risk is national schedule conversion, which multiplies volume and divides price in a single financing decision. Timing is unpredictable.
Gross Margin: 74-83%

Travel And Occupational Vaccines

Strong growth at 9.0% through private and employer channels with a clinical gate rather than any national programme. The risk is that travel demand is genuinely cyclical and collapsed entirely during recent disruption, which is a pattern that can recur without warning. Recovery took several years.
Gross Margin: 62-70%

Tendered Paediatric Supply

The volume core, covering most doses administered globally at prices around a dollar each. Manufacturers hold it because it carries facility utilisation and multilateral relationships, and because exiting removes the scale that makes everything else economically viable. Scale depends entirely on it, and nobody exits deliberately.
Gross Margin: 23-29%

Success Eroding Its Own Demand

The strategic watch-out. A vaccine that works reduces disease incidence and therefore the visible reason for vaccination, which no other therapeutic category has to plan around at all. The risk is sentiment hardening fastest exactly where programmes have performed best historically. Argument does not answer it.
Gross Margin: 26-32%

Schedules Against Individual Decisions

Two demand structures coexist and behave nothing alike. Paediatric routine immunisation is scheduled, near-universal and financed publicly, which produces predictable volume tied to birth cohorts rather than to any decision made repeatedly. Adult vaccination is decided person by person, season by season, and reaches only around 34% of those for whom it is recommended. One is demography and the other is behaviour.
Stickiness follows the same division exactly. A vaccine written into a national schedule stays there for years and is displaced only by a procurement decision or a superior product. Adult vaccination has no stickiness at the individual level at all, since the decision is remade each season and each product. What creates durability is recommendation placement and pharmacy channel presence rather than any relationship with a vaccinated person.

The decision maker could hardly differ more between the two. Paediatric supply is decided by national programme managers and multilateral procurement bodies weighing price, capacity and supply security. Adult vaccination is decided by an individual, prompted by a physician or a pharmacist and constrained by convenience. Manufacturers organised for one of those buyers reach the other only by accident, which is why so much adult opportunity remains unconverted.
vaccines-market-end-use-penetration-index-1787705470741

Two Businesses One Factory

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / COMMERCIAL STRUCTURE SEPARATION

One dollar and three hundred are different jobs

Tender supply at roughly 1.20 dollars a dose requires manufacturing scale, cost discipline and multilateral procurement relationships, while adult private vaccination at some 340 dollars a course requires physician engagement, pharmacy access and consumer marketing capability. Those skills transfer very poorly indeed between the two, and organisations running both from a single commercial structure end up genuinely optimised for neither of them. Separating those functions costs some overhead and lets each business be run by people who genuinely understand it.
02 / ACCESS INVESTMENT PRIORITY

Uptake is a scheduling problem not belief

Adult vaccination currently reaches only around 34% of eligible people even where clinical recommendation already exists, and that gap closes far more reliably through pharmacy administration, standing orders and default scheduling than through any communication programme yet attempted anywhere. Manufacturers who actively supported the regulatory change on who may administer then captured all of the volume that followed almost immediately afterwards. Communication budgets are therefore addressing a problem that was never primarily about what people happen to believe at all.
03 / CAPACITY RISK PLANNING

A lost tender strands a whole facility

Biological manufacturing capacity has to be built and then validated years before any procurement round is finally decided, and a cost of goods running near 24% of revenue leaves nothing at all to carry an underused facility afterwards. A lost tender therefore strands an entire facility rather than simply costing a contract for that particular period. Manufacturers holding portfolios that span both public and private markets are able to redeploy that capacity, while single-product specialists carry the whole exposure entirely alone.
04 / SCHEDULE CONVERSION ANTICIPATION

Volume multiplies as price divides overnight

National immunisation schedules now increasingly absorb products that were until recently private purchases only, converting revenue per dose from several hundred dollars down to a small fraction of that, in a single financing decision. Manufacturers who plan properly for that transition set their private launch pricing knowing it will eventually be superseded by tender terms instead. Those who anchor firmly on private pricing instead find that schedule inclusion negotiations become extremely difficult to conduct on any acceptable basis later on.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Vaccines Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Vaccines Exposure Evaluation 2025-26
CLIENT PROFILE
A vaccine manufacturer supplying paediatric products through multilateral and national tender alongside a growing adult portfolio in private markets, with reported vaccine revenue of 1.9 billion dollars (client-reported, unverified by MMA). Both businesses were run through a single commercial organisation. Adult uptake at served accounts tracked national averages and pharmacy channel engagement was minimal across every market.
STRATEGIC CHALLENGE
Adult vaccine launches had underperformed forecasts in three consecutive markets while tender margins compressed further each round. Management was preparing increased medical communication investment and a manufacturing cost programme. Neither addressed why adult uptake sat near national averages nor why one organisation was expected to serve two opposite buyers well.
MMA APPROACH
MMA compared adult uptake at served accounts against markets where pharmacy administration had been permitted, using coverage data the company had never analysed commercially. Twenty-one expert interviews with programme managers, procurement leads, physicians and pharmacists established how each buyer actually decides. The analysis treated commercial structure and administration access, rather than clinical communication, as the causes of underperformance.
KEY FINDINGS
  1. Adult uptake in markets permitting pharmacy administration exceeded physician-only markets substantially, and the company had made no submission supporting any of those regulatory changes.
  2. The single commercial organisation was staffed and incentivised around tender relationships, and nobody in it had consumer or pharmacy channel experience of any kind.
  3. Two adult products were priced on private market assumptions with no plan for national schedule inclusion, which programme managers described as making later negotiation very difficult.
  4. Manufacturing capacity was committed entirely against tender volume forecasts, leaving no flexibility to redeploy if a procurement round were lost. Nobody had modelled that scenario.
CLIENT PROFILE
A vaccine manufacturer supplying paediatric products through multilateral and national tender alongside a growing adult portfolio in private markets, with reported vaccine revenue of 1.9 billion dollars (client-reported, unverified by MMA). Both businesses were run through a single commercial organisation. Adult uptake at served accounts tracked national averages and pharmacy channel engagement was minimal across every market.
STRATEGIC CHALLENGE
Adult vaccine launches had underperformed forecasts in three consecutive markets while tender margins compressed further each round. Management was preparing increased medical communication investment and a manufacturing cost programme. Neither addressed why adult uptake sat near national averages nor why one organisation was expected to serve two opposite buyers well.
MMA APPROACH
MMA compared adult uptake at served accounts against markets where pharmacy administration had been permitted, using coverage data the company had never analysed commercially. Twenty-one expert interviews with programme managers, procurement leads, physicians and pharmacists established how each buyer actually decides. The analysis treated commercial structure and administration access, rather than clinical communication, as the causes of underperformance.
KEY FINDINGS
  1. Adult uptake in markets permitting pharmacy administration exceeded physician-only markets substantially, and the company had made no submission supporting any of those regulatory changes.
  2. The single commercial organisation was staffed and incentivised around tender relationships, and nobody in it had consumer or pharmacy channel experience of any kind.
  3. Two adult products were priced on private market assumptions with no plan for national schedule inclusion, which programme managers described as making later negotiation very difficult.
  4. Manufacturing capacity was committed entirely against tender volume forecasts, leaving no flexibility to redeploy if a procurement round were lost. Nobody had modelled that scenario.
RECOMMENDED STRATEGY
Phase 1: Phase one: separate the public tender and private adult commercial organisations, staffing each with people who understand what actually decides its outcomes. Phase 2: Phase two: support pharmacy administration regulatory change in priority markets, since access moves uptake faster than communication has ever managed. Phase 3: Phase three: reprice adult launches anticipating eventual schedule conversion, preserving the ability to negotiate inclusion on acceptable terms. Conversion is inevitable eventually.
OUTCOME
The two commercial organisations were separated and adult channel hiring began with pharmacy and consumer backgrounds rather than tender experience. Pharmacy administration submissions were filed in three priority markets and one change was adopted within the year (client-reported, unverified by MMA). Adult launch pricing was revised in two markets to preserve later schedule negotiation.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Vaccines Market?

The market was worth 62.0 billion dollars in 2025, covering paediatric, adult, influenza, travel, outbreak preparedness and therapeutic vaccines. It reaches 66.96 billion dollars in 2026.

How large will the Vaccines Market be by 2036?

MMA forecasts 144.56 billion dollars by 2036, an increase of 77.60 billion dollars over the 2026 base. That represents an expansion multiple of 2.16 times across the forecast period.

What is the CAGR for the Vaccines Market 2026 to 2036?

The base case compounds at 8.0% annually. The bull case reaches 9.2% if adult uptake improves toward recommendation levels, while the bear case sits at 6.8% on hardening sentiment and tighter procurement pricing.

Which segment is growing fastest?

Adult and older adult vaccines, at 12.0%, half again the market rate of 8.0%. Uptake reaches only around 34% of eligible people even where recommendation already exists.

Who are the major companies in the Vaccines Market?

Pfizer, Merck, GSK, Sanofi and Moderna lead on disclosed vaccine franchise revenue. Serum Institute of India, Bharat Biotech and Sinovac dominate dose volume without comparable revenue share.

Which country is growing fastest?

India at 10.1%, and the country also produces roughly 46% of all global vaccine doses by volume. Domestic schedule expansion and manufacturing scale are growing together.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Target Population

  • Paediatric Routine Immunisation
  • Adult and Older Adult Vaccines
  • Influenza Vaccines
  • Travel and Occupational Vaccines
  • Outbreak and Pandemic Preparedness Vaccines
  • Therapeutic and Cancer Vaccines

By End-Use Setting

  • National Immunisation Programmes
  • Retail and Community Pharmacy
  • Primary Care and Physician Offices
  • Travel Health Clinics
  • Occupational Health Services
  • Hospital and Specialist Clinics

By Commercial Dimension

  • Multilateral Procurement Supply
  • National Tender Supply
  • Private Market Retail Sale
  • Employer and Occupational Purchase
  • Government Preparedness Contract
  • Donor Financed Programme Supply

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
Scope covers human vaccines for preventive and therapeutic use across public and private markets, spanning paediatric routine immunisation, adult and older adult vaccines, influenza vaccines, travel and occupational vaccines, outbreak and pandemic preparedness vaccines, and therapeutic and cancer vaccines. Veterinary and animal health vaccines, monoclonal antibody prophylaxis and passive immunisation products, immunoglobulin and plasma-derived products, adjuvants, excipients and container systems sold as separate inputs, and vaccine administration and clinic services billed independently of product supply are excluded from the market size and all derived figures.
Quantitative Units
USD billions (current prices, net of rebates); doses administered; price per dose; adult uptake against recommendation; manufacturing capacity committed
Segmentation Dimensions
By Target Population; By End-Use Setting; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, India, Japan, Germany, France, UK, Brazil, Indonesia, South Korea, Italy, Nigeria, Mexico, Turkey, Australia
Key Companies Profiled
Pfizer, Merck & Co, GSK, Sanofi, Moderna, Serum Institute of India, Bharat Biotech, Sinovac Biotech, Sinopharm, CSL Seqirus, Novavax, Bavarian Nordic, Valneva, Takeda, Biological E, Panacea Biotec, Walvax Biotechnology, Zhifei Biological, Daiichi Sankyo, Emergent BioSolutions
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-HLT-126
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Vaccines Market Report (2026 to 2036).

The full report runs to 192 pages and covers all six target population segments, seven regions and 20 profiled manufacturers in detail. It includes the complete segment CAGR set, regional procurement and pricing structure comparison, and analysis of adult uptake against recommendation across administration access models. Company profiles carry evaluation on disclosed vaccine franchise revenue, with moat and risk assessment for the top five manufacturers. The competitive section extends to 17 tracked regulatory, procurement and corporate developments across 2024 and 2025. Primary research inputs include a quantitative survey of 3,800 respondents and 47 expert interviews conducted in Q4 2025.
Six target population segments with individual CAGR forecasts
Seven regional markets with procurement and pricing structure comparison
Twenty manufacturer profiles on consistent franchise revenue evaluation basis
Seventeen tracked procurement and regulatory developments with commercial interpretation
Adult uptake analysis compared across administration access models
Capacity commitment risk modelled against tender outcome scenarios

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts